Elevance Health, Inc. (ELV) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does Elevance Health, Inc. Do?
Elevance Health Inc. operates as a health benefits company. It supports consumers, families, and communities across the entire care journey connecting to the care, support, and resources to lead healthier lives. It serves approximately 118 million people through a portfolio of medical, digital, pharmacy, behavioral, clinical, and care solutions. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health Inc. in June 2022. Elevance Health Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana. Elevance Health, Inc. (ELV) is classified as a large-cap stock in the Financials sector, specifically within the Insurance industry. The company is led by CEO Gail K. Boudreaux and employs approximately 102,300 people, headquartered in Indianapolis, Indiana. With a market capitalization of $65.6B, ELV is one of the prominent companies in the Financials sector.
Elevance Health, Inc. (ELV) Stock Rating — Hold (April 2026)
As of April 2026, Elevance Health, Inc. receives a Hold rating with a composite score of 49.7/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.ELV ranks #1,884 out of 4,446 stocks in our coverage universe. Within the Financials sector, Elevance Health, Inc. ranks #544 of 891 stocks, placing it in the lower half of its Financials peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
ELV Stock Price and 52-Week Range
Elevance Health, Inc. (ELV) currently trades at $311.53. The stock lost $5.34 (1.7%) in the most recent trading session. The 52-week high for ELV is $458.75, which means the stock is currently trading -32.1% from its annual peak. The 52-week low is $273.71, putting the stock 13.8% above its annual trough. Recent trading volume was 1.1M shares, reflecting moderate market activity.
Is ELV Overvalued or Undervalued? — Valuation Analysis
Elevance Health, Inc. (ELV) carries a value factor score of 68/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 11.19x, compared to the Financials sector average of 14.88x — a discount of 25%. The price-to-book ratio stands at 1.56x, versus the sector average of 1.22x. The price-to-sales ratio is 0.35x, compared to 0.90x for the average Financials stock. On an enterprise value basis, ELV trades at 12.10x EV/EBITDA, versus 3.26x for the sector.
Overall, ELV's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.
Elevance Health, Inc. Profitability — ROE, Margins, and Quality Score
Elevance Health, Inc. (ELV) earns a quality factor score of 69/100, indicating solid business quality with consistent operational execution. The return on equity (ROE) is 13.9%, compared to the Financials sector average of 8.5%, which is within a healthy range. Return on assets (ROA) comes in at 5.0% versus the sector average of 1.2%.
On a margin basis, Elevance Health, Inc. reports gross margins of 89.3%. The operating margin is 4.3% (sector: 21.8%). Net profit margin stands at 3.1%, versus 17.7% for the average Financials stock. Revenue growth is running at 15.6% on a trailing basis, compared to 9.4% for the sector. The overall profitability profile is adequate, though there may be room for margin expansion.
ELV Debt, Balance Sheet, and Financial Health
Elevance Health, Inc. has a debt-to-equity ratio of 72.0%, compared to the Financials sector average of 121.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 1.54x, suggesting adequate working capital coverage. Total debt on the balance sheet is $31.90B. Cash and equivalents stand at $8.71B.
ELV has a beta of 0.30, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for Elevance Health, Inc. is 71/100, indicating low-volatility characteristics and consistent price behavior that appeals to risk-averse investors.
Elevance Health, Inc. Revenue and Earnings History — Quarterly Trend
In TTM 2026, Elevance Health, Inc. reported revenue of $194.48B and earnings per share (EPS) of $25.28. Net income for the quarter was $6.12B. Gross margin was 89.3%. Operating income came in at $8.30B.
In FY 2025, Elevance Health, Inc. reported revenue of $199.13B and earnings per share (EPS) of $25.28. Net income for the quarter was $5.66B. Gross margin was 89.4%. Revenue grew 12.5% year-over-year compared to FY 2024. Operating income came in at $7.20B.
In Q3 2025, Elevance Health, Inc. reported revenue of $50.71B and earnings per share (EPS) of $5.32. Net income for the quarter was $1.19B. Gross margin was 89.4%. Revenue grew 12.4% year-over-year compared to Q3 2024. Operating income came in at $1.29B.
In Q2 2025, Elevance Health, Inc. reported revenue of $49.78B and earnings per share (EPS) of $7.74. Net income for the quarter was $1.74B. Gross margin was 89.4%. Revenue grew 13.4% year-over-year compared to Q2 2024. Operating income came in at $2.42B.
Over the past 8 quarters, Elevance Health, Inc. has demonstrated a growth trajectory, with revenue expanding from $43.89B to $194.48B. Investors analyzing ELV stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
ELV Dividend Yield and Income Analysis
Elevance Health, Inc. (ELV) currently pays a dividend yield of 2.1%. At this yield, a $10,000 investment in ELV stock would generate approximately $$209.00 in annual dividend income. This compares to the Financials sector average dividend yield of 2.5%, meaning ELV yields less than the typical sector peer.
ELV Momentum and Technical Analysis Profile
Elevance Health, Inc. (ELV) has a momentum factor score of 27/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 27/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 24/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.
ELV vs Competitors — Financials Sector Ranking and Peer Comparison
Within the Financials sector, Elevance Health, Inc. (ELV) ranks #544 out of 891 stocks based on the Blank Capital composite score. This places ELV in the lower half of all Financials stocks in our coverage universe. Key competitors and sector peers include WHITE MOUNTAINS INSURANCE GROUP LTD (WTM) with a score of 62.9/100, OPPENHEIMER HOLDINGS INC (OPY) with a score of 62.6/100, Enact Holdings, Inc. (ACT) with a score of 61.6/100, International General Insurance Holdings Ltd. (IGIC) with a score of 61.3/100, and PARKE BANCORP, INC. (PKBK) with a score of 60.4/100.
Comparing ELV against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full ELV vs S&P 500 (SPY) comparison to assess how Elevance Health, Inc. stacks up against the broader market across all factor dimensions.
ELV Next Earnings Date
No upcoming earnings date has been announced for Elevance Health, Inc. (ELV) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy ELV? — Investment Thesis Summary
Elevance Health, Inc. presents a balanced picture with arguments on both sides. The quality score of 69/100 indicates above-average profitability and business fundamentals. The value score of 68/100 suggests attractive pricing relative to fundamentals. Momentum is weak at 27/100, a headwind for near-term performance. Low volatility (stability score 71/100) reduces downside risk.
In summary, Elevance Health, Inc. (ELV) earns a Hold rating with a composite score of 49.7/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on ELV stock.
Related Resources for ELV Investors
Explore more research and tools: ELV vs S&P 500 comparison, top Financials stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare ELV head-to-head with peers: ELV vs WTM, ELV vs OPY, ELV vs ACT.